K-Nor is indicated in patients with hyperkalemia associated with anuria or severe oliguria. It reduces serum level of potassium and removes excess potassium from the body. K-Nor is indicated in all states of hyperkalemia due to acute and chronic renal failure, abortion, complicated labor, incompatible blood transfusion, crush injury, prostectomy, severe burns, surgical shock, cases of severe glomerulonephritis and pyelonephritis. K-Nor can also be useful in patients requiring dialysis and can also be used during the period of under dialysis to control blood potassium levels.
Dosage & Administration
K-Nor is for oral or rectal administration only. Treatment with the resin should be given as soon as the serum potassium level rises above 6 mmol/L.
Adults (Including the Elderly)
a) Oral: For adults the usual dose is 15 g, 3 or 4 times a day. The resin is given by mouth as a suspension in a little water or for greater palatability, the resin may be made into a paste with some sweetened vehicle but not orange juice or other fruit juices that are known to contain potassium. The amount of fluid usually ranges from 3 to 4 ml for per gram of resin.
b) Rectal: In cases where oral administration is not possible K-Nor may be given rectally as a suspension of 30 g resin in 100 ml of 2% methylcellulose and 100 ml of water as a daily retention enema.
a) Oral: Children should be given 1 g/kg body weight of K-Nor daily in divided doses in acute hyperkalemia. In maintenance therapy the dose may be reduced to 0.5 g/kg body weight daily in divided doses.
b) Rectal: It can be given rectally suspended in a proportional amount of 10% dextrose in water. Following retention of the enema, the colon should be irrigated to ensure adequate removal of the resin.
Oral administration of K-Nor is contraindicated in neonates. Only rectal administration should be considered. With rectal administration, the minimum effective dosage within the range of 0.5 g/kg to 1 g/kg should be given diluted as for adults and with adequate irrigation to ensure recovery of the resin.
Pregnancy and lactation
K-Nor is not absorbed from the gastrointestinal tract. No data are available about the use of K-Nor in human pregnancy and lactation.
During treatment with K-Nor the possibility of severe potassium depletion should be considered. To prevent serious hypokalemia, administration of the resin should be discontinued as soon as the serum potassium level falls to 5 mmol/L. Hypomagnesemia and hypercalcemia may occur. Patients should be monitored for all electrolyte disturbances. In the event of clinically significant constipation, treatment with the resin should be discontinued until normal bowel motions are resumed. Magnesium-containing laxatives should not be used. The patient should be positioned carefully when ingesting the resin to avoid aspiration which may lead to bronchopulmonary complications.
Children and neonates: K-Nor should not be given by the oral route. In both children and neonates, particular care should be observed with rectal administration.